PDS Biotechnology Corporation

Greetings and welcome to the PDS Biotech first quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the phone presentation. If anyone can require operator assistance, please press star zero on your telephone keypad. It is now my pleasure to introduce your host, Dean Schwartz.

Thank you. You may begin.

Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's first quarter 2026 results and clinical programs update call. I'm joined on the call today by the following members of the company's management team, Dr. Frank Baduado, Chief Executive Officer, Dr. Kirk Shepherd, Chief Medical Officer, and Lars Boasgaard, Chief Financial Officer. Dr. Baduado and Dr. Shepherd will provide an overview of the company's recent highlights in its clinical development program and Mr. Bosgaard will review the financial results for the quarter ended March 31, 2026. Following management's prepared remarks, we will take questions from covering analysts. As a reminder, during this call, we will be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed. in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now, I'd like to turn the call over to Dr. Badu Addo. Frank?